

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, **Website-** www.raymedlab.com

**E-mail-** [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), **Phone no. -** 0120-2426900, 9412700300

---

**Date: 27.05.2023**

The Head- Listing Compliance  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**Scrip Code: 531207**

**Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, **i.e. Saturday, 27<sup>th</sup> day of May, 2023** (commenced at **03:00 P.M.** and concluded at **05:20 P.M.**), has inter alia approved and passed the following resolutions:

1. **The Audited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended March 31, 2023. **(Copy Enclosed)**
2. Take on record of the **Audit Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and year ended March 31, 2023. **(Copy Enclosed)**
3. The declaration of **unmodified opinion on Auditor's report** on annual financial result for the quarter and year ended March 31, 2023. **(Copy Enclosed)**

Kindly take the above information on your records.

Thanking you,

**For Raymed Labs Limited**

**Ajai Goyal**  
**Whole Time Director**  
**DIN: 02636418**

**Place: Noida**

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,

UP – 201304, Website- www.raymedlab.com

E-mail- [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), Phone no. - 0120-2426900, 9412700300

---

Date: 27.05.2023

The Head- Listing Compliance

**BSE Limited**

Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai-400001

**Scrip Code: 531207**

**Sub: Declaration on Audit Report for the year ended 31<sup>st</sup> March, 2023**

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited** that Audit report in respect to Annual Audited Standalone Financial Results for the period ended 31<sup>st</sup> March, 2023 submitted by **M/s. A Kay Mehra & Co., Chartered Accountants**, Statutory Auditor of the Company is with **unmodified opinion** of the Statutory Auditor.

Thanking you,

**For Raymed Labs Limited**

**Ajai Goyal**

**Whole Time Director**

**DIN: 02636418**

**Place: Noida**



# A. KAY. MEHRA & CO.

C H A R T E R E D   A C C O U N T A N T S

2470 (BASEMENT), HUDSON LINE,  
G.T.B. NAGAR, DELHI-110009  
NEAR GTB NAGAR METRO STATION,  
Ph. No.: 011- 42461274, 9891295255  
E- Mail: akmca1969@gmail.com  
Website: www.akmca.in

## INDEPENDENT AUDITORS' REPORT ON STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31<sup>ST</sup> MARCH, 2023

To,  
THE BOARD OF DIRECTORS OF  
RAYMED LABS LIMITED  
103 EMPEROR 1, SUPERTECH EMERALD COURT,  
SECTOR 93A, NOIDA - 201304,

### Report on the audit of the Financial Results

#### Opinion

We have audited the accompanying statement of quarterly and year to date financial results of RAYMED LABS LIMITED ("the Company") for the quarter ended March 31, 2023 and for the year ended March 31, 2023 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Regulation").

In our opinion and to the best of our information and according to the explanations given to us, these Financial Results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard;
- and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2023 and for the year ended March 31, 2023.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Management's and Board of Director Responsibilities for the Financial Results

These quarterly financial results as well as the year-to-date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other





# A. KAY. MEHRA & CO.

C H A R T E R E D   A C C O U N T A N T S

2470 (BASEMENT), HUDSON LINE,  
G.T.B. NAGAR, DELHI-110009  
NEAR GTB NAGAR METRO STATION,  
Ph. No.: 011- 42461274, 9891295255  
E- Mail: akmca1969@gmail.com  
Website: www.akmca.in

comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to

*P. P. P. P.*





# A. KAY. MEHRA & CO.

CHARTERED ACCOUNTANTS

2470 (BASEMENT), HUDSON LINE,  
G.T.B. NAGAR, DELHI-110009  
NEAR GTB NAGAR METRO STATION,  
Ph. No.: 011- 42461274, 9891295255  
E- Mail: akmc1969@gmail.com  
Website: www.akmca.in

continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter (if any)

We draw attention to:

- (1) During the year Company's administrative & other general expenses are paid by Ajay Goyal (Director) on behalf of the company.
- (2) Material Uncertainty Related to Going Concern  
The Company is not doing any business operations from past more than three years and neither searching for any revenue-generating opportunity during the year.

Our opinion is not modified in respect of this matter.

The Statement includes the results for the Quarter ended March 31, 2023 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our report is not modified in respect of these matters.

For A. Kay. Mehra & Co.  
Chartered Accountants  
FRN: (050004C)

*Deepak Suneja*

CA Deepak Suneja  
Membership No- 501957  
Date: 27-May-2023

UDIN- 23501957BGVOPX4224



**Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2023**

Particulars	Amt. (In Lakhs)					
	Quarter Ended			Year Ended		
	31st March, 2023	31st Dec, 2022	31st March, 2022	31st March, 2023	31st March, 2022	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
<b>I. Revenue from Operations</b>	0.00	0.00	0.00	0.00	0.00	
<b>II. Other Income</b>	2.06	0.00	0.00	2.06	0.00	
<b>III. Total Income (I +II)</b>	<b>2.06</b>	<b>0.00</b>	<b>0.00</b>	<b>2.06</b>	<b>0.00</b>	
<b>IV. Expenses</b>						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	
Employee Benefits Expenses	0.90	0.90	0.65	3.75	2.82	
Finance Costs	0.00	0.00	0.00	0.00	0.00	
Depreciation and amortisation expenses	0.19	0.12	0.13	0.56	0.52	
Other Expenses	8.86	0.60	3.61	14.84	4.87	
<b>Total Expenses (IV)</b>	<b>9.95</b>	<b>1.62</b>	<b>4.39</b>	<b>19.15</b>	<b>8.21</b>	
<b>V. Profit/(Loss) before exceptional items and tax (III- IV)</b>	<b>-7.89</b>	<b>-1.62</b>	<b>-4.39</b>	<b>-17.09</b>	<b>-8.21</b>	
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00	
<b>VII. Profit/(Loss) before tax (V-VI)</b>	<b>-7.89</b>	<b>-1.62</b>	<b>-4.39</b>	<b>-17.09</b>	<b>-8.21</b>	
<b>VIII. Tax Expense</b>						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	
<b>IX. Profit/(Loss) for the period from continuing operations (VII-VIII)</b>	<b>-7.89</b>	<b>-1.62</b>	<b>-4.39</b>	<b>-17.09</b>	<b>-8.21</b>	
<b>X. Profit/(Loss) from discontinued operations</b>	0.00	0.00	0.00	0.00	0.00	
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	
<b>XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
<b>XIII. Profit/(Loss) for the period (IX+XII)</b>	<b>-7.89</b>	<b>-1.62</b>	<b>-4.39</b>	<b>-17.09</b>	<b>-8.21</b>	
<b>XIV. Other Comprehensive Income</b>	0.00	0.00	0.00	0.00	0.00	
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
<b>XV. Total Comprehensive Income for the period (XIII+XIV)</b>	<b>-7.89</b>	<b>-1.62</b>	<b>-4.39</b>	<b>-17.09</b>	<b>-8.21</b>	
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)						
<b>XVI. Paid up Equity Share Capital (Face Value of Rs. 10 Each)</b>	427.35	427.35	427.35	427.35	427.35	
<b>XVII. Other Equity</b>	0.00	0.00	0.00	-657.94	-640.85	
<b>XIX. Earnings per equity share (for continuing operation):</b>						
(1) Basic	-0.1847	-0.0379	-0.1028	-0.3999	-0.1921	
(2) Diluted	-0.1847	-0.0379	-0.1028	-0.3999	-0.1921	
<b>XX. Earnings per equity share (for discontinued operation):</b>						
(1) Basic	0.000	0.000	0.000	0.000	0.000	
(2) Diluted	0.000	0.000	0.000	0.000	0.000	
<b>XXI. Earnings per equity share (for discontinued &amp; continuing operations)</b>						
(1) Basic	-0.1847	-0.0379	-0.1028	-0.3999	-0.1921	
(2) Diluted	-0.1847	-0.0379	-0.1028	-0.3999	-0.1921	

**Notes:**

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 27, May 2023. The Statutory Auditors have carried out their audit for the above results.
- (2) The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- (3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (4) During the 4th Quarter of the Financial Year 2022-23 Company has written off Rs 2.06 Lakh from Creditors/ Payable balances and Rs 8.51 Lakh unrecoverable debtors balances which are included in Other Expenses of the Financial Result.
- (5) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- (6) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.
- (7) The figures of the last quarters are the balancing figures between audited figures in respect of the full financial year up to March 31, 2023 and March 31, 2022 and the unaudited published year-to-date figures up to December 31, 2022 and December 31, 2021, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

**For Raymed Labs Limited**

**Ajai Goyal**  
 Wholetime Director  
 DIN : 02636418

**Date: 27.05.2023**  
 Place : Noida

<b>Raymed Labs Limited</b> Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240 E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300
---

<b>Statement of Audited Standalone Assets and Liabilities for the year ended March 31, 2023</b> Amount in Lakhs.
---

Particulars	As at 31st March, 2023	As at 31st March, 2022
	(Audited)	(Audited)
<b>ASSETS</b>		
<b>Non current assets</b>		
(a) Property, Plant and Equipment	15.05	15.56
(b) Capital Work in Progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.03
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financials Assets-		
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(iii) Loans	0.00	0.00
(iv) Other(to be specified)	0.00	0.00
(i) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	0.00	0.00
<b>Current Assets</b>		
(a) Inventories	0.00	0.00
(b) Financials Assets		
(i) Investments	0.00	0.00
(ii) Trade receivables	0.00	2.49
(iii) Cash and cash equivalents	0.00	0.05
(iv) Bank Balance other than (iii) above	0.05	0.02
(v) Loans	0.00	6.10
(vi) Others (to be specified)	0.00	0.00
(c) Current tax Assets	0.00	0.00
(d) Other current Assets	0.45	0.28
<b>TOTAL ASSETS</b>	<b>15.55</b>	<b>24.53</b>
<b>EQUITY AND LIABILITES</b>		
<b>Equity-</b>		
(a) Equity Share Capital	427.35	427.35
(b) Other Equity	-657.94	-640.85
<b>Liabilities</b>		
<b>Non -Current liabilities</b>		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payable	0.00	0.00
(iii) Other Financial liabilities (other than specified in item (b) to be specified)	237.10	220.74
(b) Provisions	0.00	0.00
(c) Deffered Tax Liabilities (net)	0.00	0.00
(d) Other Non-Current Liabilities	0.00	0.00
<b>Current Liabilities</b>		
(a) Financials Liabilities		
(i) Borrowings	0.00	0.00
(ii) Trade Payables	3.84	5.32
(iii) Other Financial liabilities (other than specified in item (c) to be specified)	5.00	5.00
(b) Other current liabilities	0.20	0.49
(c) provisions	0.00	6.48
(d) Current Tax Liabilities	0.00	0.00
<b>TOTAL EQUITY AND LIABILITES</b>	<b>15.55</b>	<b>24.53</b>

For Raymed Labs Limited

Ajai Goyal  
 Wholetime Director  
 DIN : 02636418

Date: 27.05.2023  
 Place : Noida

**Raymed Labs Limited**  
**Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,**  
**Uttar Pradesh, CIN: L24111UP1992PLC014240**  
**E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,**  
**Tel: 0120-2426900, 9412700300**

**STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2023**

	Amount in Lakh	
	Year ended March 31, 2023 (01.04.2022 to 31.03.2022) (Audited)	Year ended March 31, 2022 (01.04.2021 to 31.03.2022) (Audited)
<b>Particulars</b>		
<b>Cash flow from Operating Activities</b>		
Profit Before Tax	-17.09	-8.21
<b>Adjustments for</b>		
Adjustments for finance costs	0	0
Adjustments for decrease (increase) in inventories	0	0
Adjustments for decrease (increase) in trade receivables, current	0.00	0
Adjustments for decrease (increase) in trade receivables, non-current	0	0
Adjustments for decrease (increase) in other current assets	0	0
Adjustments for other financial assets, non-current	0	0
Adjustments for other financial assets, current	0	0
Adjustments for other bank balances	0	0
Adjustments for increase (decrease) in trade payables, current	0.00	-0.28
Adjustments for increase (decrease) in trade payables, non-current	0	0
Adjustments for increase (decrease) in other current liabilities	0	0.21
Adjustments for increase (decrease) in other non-current liabilities	0	0
Adjustments for depreciation and amortisation expense	0.56	0.52
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0	0
Adjustments for provisions, current	-6.48	3.24
Adjustments for provisions, non-current	0	0
Adjustments for other financial liabilities, current	0	0.00
Adjustments for other financial liabilities, non-current	0.00	4.41
Adjustments for unrealised foreign exchange losses/gains	0	0
Adjustments for dividend income	0	0
Adjustments for interest income	0	0
Adjustments for share-based payments	0	0
Adjustments for fair value losses (gains)	0	0
Adjustments for undistributed profits of associates	0	0
Other adjustments for which cash effects are investing or financing cash flow	0	0
Other adjustments to reconcile profit (loss)	0	0
Other adjustments for non-cash items	6.65	0
Share of profit and loss from partnership firm or association of persons or limited liability partnership	0	0
<b>Total adjustments for reconcile profit (loss)</b>	17.07	8.10
<b>Net cash flows from (used in) operations</b>	-0.02	-0.11
Dividends received	0	0
Interest paid	0	0
Interest received	0	0
Income taxes paid (refund)	0	0
Other inflows (outflows) of cash	0	0
<b>Net cash flows from (used in) operating activities</b>	-0.02	-0.11
<b>Cash flows from used in investing activities</b>		
Cash flows from losing control of subsidiaries or other businesses	0	0
Cash flows used in obtaining control of subsidiaries or other businesses	0	0
Other cash receipts from sales of equity or debt instruments of other entities	0	0
Other cash payments to acquire equity or debt instruments of other entities	0	0
Other cash receipts from sales of interests in joint ventures	0	0
Other cash payments to acquire interests in joint ventures	0	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0	0
Proceeds from sales of property, plant and equipment	0	0
Purchase of property, plant and equipment	0	0
Proceeds from sales of investment property	0	0
Purchase of investment property	0	0
Proceeds from sales of intangible assets	0	0
Purchase of intangible assets	0	0
Proceeds from sales of intangible assets under development	0	0
Purchase of intangible assets under development	0	0
Proceeds from sales of goodwill	0	0
Purchase of goodwill	0	0
Proceeds from biological assets other than bearer plants	0	0
Purchase of biological assets other than bearer plants	0	0
Proceeds from government grants	0	0
Proceeds from sales of other long-term assets	0	0
Cash receipts from repayment of advances and loans made to other parties	0	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0	0
Dividends received	0	0
Interest received	0	0
Income taxes paid (refund)	0	0
Other inflows (outflows) of cash	0	0
<b>Net cash flows from (used in) investing activities</b>	0	0
<b>Cash flows from used in financing activities</b>		
Proceeds from changes in ownership interests in subsidiaries	0	0
Payments from changes in ownership interests in subsidiaries	0	0
Proceeds from issuing shares	0	0
Proceeds from issuing other equity instruments	0	0
Payments to acquire or redeem entity's shares	0	0
Payments of other equity instruments	0	0

Proceeds from exercise of stock options	0	0
Proceeds from issuing debentures notes bonds etc	0	0
Proceeds from borrowings	0	0
Repayments of borrowings	0	0
Payments of finance lease liabilities	0	0
Payments of lease liabilities	0	0
Dividends paid	0	0
Interest Paid	0	0
Income taxes paid (refund)	0	0
Other inflows (outflows) of cash	0	0
<b>Net cash flows from (used in) financing activities</b>	<b>0</b>	<b>0</b>
<b>Net increase (decrease) in cash and cash equivalents before effect of exchange ratechanges</b>	<b>-0.02</b>	<b>-0.11</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>0</b>	<b>0</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>0</b>	<b>0</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-0.02</b>	<b>-0.11</b>
Cash and cash equivalents cash flow statement at beginning of period	0.07	0.18
<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>0.05</b>	<b>0.07</b>

**Notes:**

The above results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 27th May, 2023. The Statutory auditors have conducted the audit of the above financial results and have expressed an unmodified report on the same.

**For Raymed Labs Limited**

(Ajai Goyal)  
**Whole time Director**  
**DIN: 02636418**

**Date: 27.05.2023**  
**Place: Noida**